The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for ...

We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going ...

Families say it's 'completely frustrating' that children with Duchenne Muscular Dystrophy are being denied access to free ...

In this case the FDA said Sarepta’s data showing an increase in production of dystrophin – the protein that preserves muscle that is lacking in DMD patients – is likely to predict a clinical ...

Ezutromid was designed to treat DMD by boosting utrophin levels to compensate for the faulty dystrophin protein that is the root cause of the very rare muscle-wasting disease. Summit reported ...

2024 — Researchers have made a significant breakthrough in developing a new gene therapy approach that restores full-length dystrophin protein, which could lead to new treatments for people with ...

It's been nearly two years since Elevidys, a gene therapy for Duchenne MD developed by Sarepta Therapeutics, was approved by ...

Protein shakes have become increasingly popular among fitness enthusiasts, but the optimal timing for consumption remains a topic of debate. While post-workout protein intake was once considered ...